SNGX•benzinga•
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Summary
Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 14, 2025 by benzinga